120,010 Shares in Annexon, Inc. $ANNX Acquired by Ieq Capital LLC

Ieq Capital LLC acquired a new position in shares of Annexon, Inc. (NASDAQ:ANNX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 120,010 shares of the company’s stock, valued at approximately $685,000. Ieq Capital LLC owned approximately 0.07% of Annexon as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Annexon in the second quarter valued at $77,312,000. Redmile Group LLC grew its holdings in shares of Annexon by 44.8% during the first quarter. Redmile Group LLC now owns 14,549,768 shares of the company’s stock valued at $80,606,000 after buying an additional 4,499,124 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in Annexon by 266.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,500,000 shares of the company’s stock valued at $27,610,000 after buying an additional 4,000,000 shares during the period. Siren L.L.C. acquired a new position in Annexon during the first quarter valued at $21,931,000. Finally, Mak Capital One LLC purchased a new stake in Annexon in the 4th quarter worth about $14,852,000.

Analyst Ratings Changes

Several equities analysts have weighed in on ANNX shares. Citigroup assumed coverage on Annexon in a research note on Tuesday, July 21st. They set a “market underperform” rating on the stock. Needham & Company LLC increased their price target on shares of Annexon from $11.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen cut shares of Annexon from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Citizens Jmp raised shares of Annexon from an “underperform” rating to a “market perform” rating in a research report on Thursday, August 13th. Finally, The Goldman Sachs Group started coverage on shares of Annexon in a research note on Tuesday, May 12th. They issued a “neutral” rating and a $7.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $15.33.

Annexon Trading Up 5.2%

ANNX opened at $5.25 on Friday. The stock has a fifty day moving average price of $5.41 and a 200 day moving average price of $5.44. Annexon, Inc. has a 1 year low of $2.03 and a 1 year high of $7.18. The stock has a market cap of $995.29 million, a price-to-earnings ratio of -4.53 and a beta of 1.18.

Annexon (NASDAQ:ANNX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). As a group, sell-side analysts forecast that Annexon, Inc. will post -1.01 earnings per share for the current fiscal year.

Annexon Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.